Center For Mental Health Vratsa EOOD — Clinical Trial Site

20 Registered trials

8 Currently recruiting

Organisation

Center For Mental Health Vratsa EOOD

Location

Vratsa, Bulgaria

Identifier

ORG-100043393

Address

Belasita Str 1, 3000, Bulgaria

Departments

Center For Mental Health Vratsa EOOD
Daily Inpatient Unit
Department of General Psychiatry
Department of General Psychiatry
Department of General Psychiatry Psychiatry-Level III
General Psychiatry
N/A
psychiatry

Clinical trials at this site (20)

Search interface

A Randomized, Multiple-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 and the Relative Bioavaila… Pending

2023-508981-13-00 Schizophrenia 2
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) - X-CE… Pending

2025-522775-29-00 Depressive episodes associated with Bipolar disorder I 5
An Open-label Study of Azetukalner in Bipolar I or II Depression Pending

2025-522872-10-00 Depressive episodes associated with Bipolar disorder I 5
A Phase 2 Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults with Schizophrenia (STAR-1) Pending

2025-524058-32-00 Schizophrenia 4
Long-Term Safety and Tolerability of NBI-1117568 in Adults with Schizophrenia Recruiting

2025-521216-19-00 Schizophrenia 5 2025-12-10
A Phase 3 Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting

2024-520259-26-00 Mania or Mania with Mixed Features in Bipolar-I Disorde 5 2025-09-25
DT-101 in Adults with Major Depressive Disorder Recruiting

2025-522784-15-00 Major Depressive Disorder 4 2026-03-24
Evaluation of NBI-1117568 in Inpatient Adults with Schizophrenia Recruiting

2025-521215-39-00 Schizophrenia 5 2025-12-08
A study to assess the efficacy and safety of ITI-1284 as adjunctive treatment in patients with Generalized Anxiety Disorder Recruiting

2024-513302-56-00 Generalized Anxiety Disorder 4 2025-11-17
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting

2024-520165-32-00 BP-I mania or mania with mixed features 5 2025-11-04
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder Recruiting

2024-520333-68-00 Major Depressive Disorder 5 2025-09-26
A study to assess the efficacy and safety of ITI-1284 in the treatment of Psychosis Associated with Alzheimer's Disease Recruiting

2024-513035-25-00 Psychosis associated with Alzheimer’s Disease 4 2025-07-11
A study to assess the efficacy and safety of lumateperone in patients with Bipolar Mania Ended

2024-513036-26-00 Bipolar I Disorder (Bipolar Mania) 5 2024-12-20
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in … Ended

2024-511057-22-00 Major Depressive Disorder (MDD) with Moderate-to-severe 5 2024-12-04
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy a… Ended

2024-513104-34-00 Major Depressive Disorder 4 2024-11-25
A rollover study for subjects that complete KAR-012 trial, to assess Long-term Safety and Tolerability of Adjunctive KarXT in Subjects with … Ended

2024-510773-20-00 Schizophrenia 5 2023-06-12
Protocol Lay Person Short Title: A Trial of the Safety and Efficacy of Flexible Doses of SEP-363856 as Adjunctive Therapy in the Treatment o… Ended

2022-500538-27-00 Adjunctive therapy to antidepressants for the treatmen 10 2023-03-30
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) Ended

2024-510770-25-00 Schizophrenia 5 2023-03-22
A 52-week, Open-label Trial of CVL-231 in Adult Participants With Schizophrenia Ended

2024-511441-19-00 Schizophrenia 4 2023-03-08
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia Ended

2023-508433-14-00 Schizophrenia 5 2022-09-30